These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36135828)

  • 21. [The glucagon-like peptide-1 receptor-agonist semaglutide].
    Boje AD; Juhl CR; Torekov SS; Madsbad S
    Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review.
    Alorfi NM; Algarni AS
    Clin Pharmacol; 2022; 14():61-67. PubMed ID: 35958046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
    Lau DCW; Batterham RL; le Roux CW
    Expert Rev Clin Pharmacol; 2022 Mar; 15(3):251-267. PubMed ID: 35466848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semaglutide is effective in type 2 diabetes and obesity with schizophrenia.
    Noda K; Kato T; Nomura N; Sakai M; Kubota S; Hirose T; Liu Y; Takahashi Y; Takao K; Mizuno M; Hirota T; Suwa T; Horikawa Y; Yabe D
    Diabetol Int; 2022 Oct; 13(4):693-697. PubMed ID: 36117924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
    Bandyopadhyay I; Dave S; Rai A; Nampoothiri M; Chamallamudi MR; Kumar N
    Curr Drug Targets; 2022; 23(3):311-327. PubMed ID: 34468297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
    Iacobellis G; Villasante Fricke AC
    J Endocr Soc; 2020 Apr; 4(4):bvz042. PubMed ID: 32190806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
    Scheen AJ
    Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leg to leg bioelectrical impedance analysis of percentage fat mass in obese patients-Can it tell us more than we already know?
    Dixon JB; Bhasker AG; Lambert GW; Lakdawala M
    Surg Obes Relat Dis; 2016 Aug; 12(7):1397-1402. PubMed ID: 27134197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice.
    Reis-Barbosa PH; Marcondes-de-Castro IA; Marinho TS; Aguila MB; Mandarim-de-Lacerda CA
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101922. PubMed ID: 35427802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
    Gallwitz B; Giorgino F
    Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes.
    Raven LM; Greenfield JR; Muir CA
    JCEM Case Rep; 2023 Jan; 1(1):luac017. PubMed ID: 37908242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review).
    Tilinca MC; Tiuca RA; Niculas C; Varga A; Tilea I
    Exp Ther Med; 2021 Oct; 22(4):1167. PubMed ID: 34504612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
    Brunton SA; Mosenzon O; Wright EE
    Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.
    Mahapatra MK; Karuppasamy M; Sahoo BM
    Pharm Res; 2022 Jun; 39(6):1233-1248. PubMed ID: 35650449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Semaglutide outperforms insulin in restoring neutrophil function against implant-related infection in diabetic and obese mice: experimental research.
    Liu T; Zhou L; Chen Y; Lin J; Zhu H
    Int J Surg; 2024 Jun; ():. PubMed ID: 38935106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Semaglutide for the Treatment of Type 2 Diabetes Mellitus.
    Miles KE; Kerr JL
    J Pharm Technol; 2018 Dec; 34(6):281-289. PubMed ID: 34861016
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice.
    Liu D; Gu J; Shao W; Pang J; Qian X; Jin T
    Can J Diabetes; 2022 Apr; 46(3):216-224.e2. PubMed ID: 35568421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
    Bucheit JD; Pamulapati LG; Carter N; Malloy K; Dixon DL; Sisson EM
    Diabetes Technol Ther; 2020 Jan; 22(1):10-18. PubMed ID: 31436480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study.
    Hepprich M; Zillig D; Florian-Reynoso MA; Donath MY; Rudofsky G
    Diabetes Ther; 2021 Mar; 12(3):943-954. PubMed ID: 33615400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis.
    Alhindi Y; Avery A
    Contemp Clin Trials Commun; 2022 Aug; 28():100944. PubMed ID: 35812819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.